TY - JOUR
T1 - The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls
AU - Broocks, Andreas
AU - Little, John T.
AU - Martin, Alex
AU - Minichiello, Marcia D.
AU - Dubbert, Bellinda
AU - Mack, Carol
AU - Tune, Larry
AU - Murphy, Dennis L.
AU - Sunderland, Trey
PY - 1998/3/15
Y1 - 1998/3/15
N2 - Background: There is evidence from animal and human experiments that leading and memory come under the separate influence of both cholinergic and serotonergic pathways. We were interested in learning whether serotonergic drugs could attenuate or exacerbate the memory-impairing effects of anticholinergic blockade in humans. Methods: The selective serotonin 5-HT3 receptor antagonist ondansetron (0.15 mg/kg IV) and the serotonergic agent m- chlorophenylpiperazine (m-CPP; 0.08 mg/kg IV) were administered in combination with the anticholinergic agent scopolamine (0.4 mg PO) and compared to scopolamine alone in 10 young, healthy volunteers. Testing occurred on three separate days. Results: As expected, IV administration of scopolamine induced significant impairments in episodic memory and processing speed; however, these scopolamine-induced cognitive deficits were not attenuated by pretreatment with IV ondansetron (0.15 mg/kg), nor were they exacerbated by administration of IV m-CPP (0.8 mg/kg) in addition to scopolamine; however, administration of IV m-CPP was followed by a significant increase of self-rated functional impairment, altered self- reality, and dysphoria ratings, and scopolamine's effect on pupil size was potentiated. Conclusions: Together, these results suggest that in young, healthy volunteers scopolamine-induced changes of cognitive performance are only minimally modulated by the serotonergic effects on ondansetron and m- CPP. Further studies with older controls are needed to test whether these findings may be influenced by age.
AB - Background: There is evidence from animal and human experiments that leading and memory come under the separate influence of both cholinergic and serotonergic pathways. We were interested in learning whether serotonergic drugs could attenuate or exacerbate the memory-impairing effects of anticholinergic blockade in humans. Methods: The selective serotonin 5-HT3 receptor antagonist ondansetron (0.15 mg/kg IV) and the serotonergic agent m- chlorophenylpiperazine (m-CPP; 0.08 mg/kg IV) were administered in combination with the anticholinergic agent scopolamine (0.4 mg PO) and compared to scopolamine alone in 10 young, healthy volunteers. Testing occurred on three separate days. Results: As expected, IV administration of scopolamine induced significant impairments in episodic memory and processing speed; however, these scopolamine-induced cognitive deficits were not attenuated by pretreatment with IV ondansetron (0.15 mg/kg), nor were they exacerbated by administration of IV m-CPP (0.8 mg/kg) in addition to scopolamine; however, administration of IV m-CPP was followed by a significant increase of self-rated functional impairment, altered self- reality, and dysphoria ratings, and scopolamine's effect on pupil size was potentiated. Conclusions: Together, these results suggest that in young, healthy volunteers scopolamine-induced changes of cognitive performance are only minimally modulated by the serotonergic effects on ondansetron and m- CPP. Further studies with older controls are needed to test whether these findings may be influenced by age.
KW - Cognitive performance
KW - Ondansetron
KW - Scopolamine
KW - m-chlorophenylpiperazine
UR - http://www.scopus.com/inward/record.url?scp=0344476213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344476213&partnerID=8YFLogxK
U2 - 10.1016/S0006-3223(97)00388-0
DO - 10.1016/S0006-3223(97)00388-0
M3 - Article
C2 - 9532345
AN - SCOPUS:0344476213
SN - 0006-3223
VL - 43
SP - 408
EP - 416
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 6
ER -